Author + information
- Pyung Chun Oh,
- Jongwook Yu,
- Kyunghee Byun,
- Myeongjoo Son,
- Minsu Kim,
- Soon Yong Suh,
- Kyounghoon Lee,
- Seung Hwan Han,
- Taehoon Ahn,
- Eak Kyun Shin and
- Woong Chol Kang
Background: Soluble ST2 has shown to be an independent predictor for adverse outcome in heart failure. We evaluated the prognostic value of soluble ST2 in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI).
Methods: A total of 323 patients with STEMI undergoing primary PCI were enrolled and divided into two groups based on the median level of ST-2 measured at the time of presentation: the high ST2 group (ST2 ≥327 pg/mL, n=162) and the low ST2 group (ST2 <327 pg/mL, n=161). The primary endpoint was 1-year major adverse cardiovascular and cerebrovascular events (MACCE), defined as the composite of all-cause death, non-fatal MI, non-fatal stroke, and ischemia-driven revascularization.
Results: Demographic, echocardiographic and angiographic characteristics were similar between the high and low ST2 groups. The cumulative incidence of MACCE at 1 year was significantly higher in the high ST2 group than in the low ST2 group (15.4% vs. 8.1%, P=0.044, Figure). By multivariate Cox regression analysis adjusting for age, sex, diabetes and blood test measured at the time of presentation including troponin I, hsCRP, NT-proBNP and hepatic transaminase, the high ST2 level was independently associated with 1-year MACCE (adjusted hazard ratio 2.15, 95% CI 1.02-4.54, p=0.044).
Conclusions: The level of ST2 measured at the time of presentation can be a powerful, independent predictor of 1-year adverse clinical outcomes in patients with STEMI.
Poster Hall, Hall C
Friday, March 17, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Coronary Angiography, Intra-Vascular Imaging, Revascularization and Outcomes
Abstract Category: 2. Acute and Stable Ischemic Heart Disease: Clinical
Presentation Number: 1166-342
- 2017 American College of Cardiology Foundation